CB2 Receptor Activation Attenuates Microcirculatory Dysfunction During Cerebral Ischemic/reperfusion Injury

Overview

Journal Microvasc Res

Specialty Cardiology & Vascular Diseases

Date 2009 Apr 1

PMID 19332079

Citations 71

Authors

Ming Zhang

Martin W Adler

Mary E Abood

Doina Ganea

Jack Jallo

Ronald F Tuma

Affiliations

Soon will be listed here.

Abstract

Previous studies from our laboratory indicated that selective cannabinoid CB(2) agonists were able to attenuate cerebral ischemia/reperfusion (I/R) injury. The goal of current study is to further test whether this attenuation involves cerebral microcirculatory function during I/R injury. Middle cerebral artery occlusion with reperfusion (MCAO/R) was performed in male mice. A selective CB(2) agonist was administered at different dosages and different times. Cerebral infarction volume, neurological function and cerebral microcirculatory function (leukocyte/endothelial interactions, cell adhesion molecule expression and blood-brain barrier disruption) were examined in vivo and in vitro. CB(2) knockout mice were subjected to MCAO/R following same procedures. Administration of the CB(2) agonist at middle dosage exerted optimal effects in reducing cerebral infarction and improving neurological function compared with other dosage groups and control group. Treatment with the CB(2) agonist at the optimal dose was still effective when given 3 h after MCAO. Transient ischemia significantly increased leukocyte/endothelial interactions, adhesion molecules expression and blood-brain barrier disruption which were all attenuated by pre-treatment with a CB(2) agonist. CB(2) knockout mice showed larger cerebral infarction and worse neurological function compared to wide type. In conclusion, CB(2) activation contributed to protecting the brain through the attenuation of cerebral microcirculatory dysfunction during cerebral I/R injury.

Citing Articles

The Effects of Cannabinoids on Ischemic Stroke-Associated Neuroinflammation: A Systematic Review.

Alraddadi E, Aljuhani F, Alsamiri G, Hafez S, Alselami G, Almarghalani D J Neuroimmune Pharmacol. 2025; 20(1):12.

PMID: 39899062 PMC: 11790784. DOI: 10.1007/s11481-025-10171-z.

Aquaporin 4 and the endocannabinoid system: a potential therapeutic target in brain injury.

Martinez-Torres A, Moran J Exp Brain Res. 2024; 242(9):2041-2058.

PMID: 39043897 PMC: 11306651. DOI: 10.1007/s00221-024-06896-7.

-Caryophyllene Inhibits Monoacylglycerol Lipase Activity and Increases 2-Arachidonoyl Glycerol Levels In Vivo: A New Mechanism of Endocannabinoid-Mediated Analgesia?.

Klawitter J, Weissenborn W, Gvon I, Walz M, Klawitter J, Jackson M Mol Pharmacol. 2024; 105(2):75-83.

PMID: 38195158 PMC: 10794982. DOI: 10.1124/molpharm.123.000668.

Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery.

Bietar B, Tanner S, Lehmann C Int J Mol Sci. 2023; 24(23).

PMID: 38069049 PMC: 10705908. DOI: 10.3390/ijms242316728.

Delta 9-tetrahydrocannabinol conserves cardiovascular functions in a rat model of endotoxemia: Involvement of endothelial molecular mechanisms and oxidative-nitrative stress.

Banyai B, Repas C, Miklos Z, Johnsen J, Horvath E, Benko R PLoS One. 2023; 18(6):e0287168.

PMID: 37327228 PMC: 10275432. DOI: 10.1371/journal.pone.0287168.

References

Lindsberg P, Carpen O, Paetau A, Karjalainen-Lindsberg M, Kaste M . Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation. 1996; 94(5):939-45. DOI: 10.1161/01.cir.94.5.939. View

Gonzalez-Rey E, Varela N, Sheibanie A, Chorny A, Ganea D, Delgado M . Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci U S A. 2006; 103(11):4228-33. PMC: 1449675. DOI: 10.1073/pnas.0508997103. View

Zhang M, Martin B, Adler M, Razdan R, Jallo J, Tuma R . Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab. 2007; 27(7):1387-96. PMC: 2637559. DOI: 10.1038/sj.jcbfm.9600447. View

Lin T, He Y, Wu G, Khan M, Hsu C . Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993; 24(1):117-21. DOI: 10.1161/01.str.24.1.117. View

Darmani N, Janoyan J, Kumar N, Crim J . Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav. 2003; 75(4):777-87. DOI: 10.1016/s0091-3057(03)00150-3. View

Klein T, Cabral G . Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol. 2007; 1(1):50-64. DOI: 10.1007/s11481-005-9007-x. View

Gupta Y, Sinha K, Chaudhary G . Transient focal ischemia induces motor deficit but does not impair the cognitive function in middle cerebral artery occlusion model of stroke in rats. J Neurol Sci. 2002; 203-204:267-71. DOI: 10.1016/s0022-510x(02)00303-9. View

Pazos M, Nunez E, Benito C, Tolon R, Romero J . Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav. 2005; 81(2):239-47. DOI: 10.1016/j.pbb.2005.01.030. View

Gasche Y, Copin J, Sugawara T, Fujimura M, Chan P . Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001; 21(12):1393-400. DOI: 10.1097/00004647-200112000-00003. View

10.

Ghosh S, Preet A, Groopman J, Ganju R . Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol. 2006; 43(14):2169-79. DOI: 10.1016/j.molimm.2006.01.005. View

11.

Nagayama T, Sinor A, Simon R, Chen J, Graham S, Jin K . Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999; 19(8):2987-95. PMC: 6782289. View

12.

Ramirez B, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos M . Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005; 25(8):1904-13. PMC: 6726060. DOI: 10.1523/JNEUROSCI.4540-04.2005. View

13.

Mauler F, Horvath E, De Vry J, Jager R, Schwarz T, Sandmann S . BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 2003; 9(4):343-58. PMC: 6741701. DOI: 10.1111/j.1527-3458.2003.tb00259.x. View

14.

Ni X, Geller E, Eppihimer M, Eisenstein T, Adler M, Tuma R . Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler. 2004; 10(2):158-64. DOI: 10.1191/1352458504ms1009oa. View

15.

Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva F, Bilbao A, Cippitelli A, Navarro M . The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2004; 40(1):2-14. DOI: 10.1093/alcalc/agh110. View

16.

Vannucci S, Willing L, Goto S, Alkayed N, Brucklacher R, Wood T . Experimental stroke in the female diabetic, db/db, mouse. J Cereb Blood Flow Metab. 2001; 21(1):52-60. DOI: 10.1097/00004647-200101000-00007. View

17.

Yang G, Gong C, Qin Z, Ye W, Mao Y, Bertz A . Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport. 1998; 9(9):2131-4. DOI: 10.1097/00001756-199806220-00041. View

18.

Parmentier-Batteur S, Jin K, Mao X, Xie L, Greenberg D . Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci. 2002; 22(22):9771-5. PMC: 6757835. View

19.

Golech S, McCarron R, Chen Y, Bembry J, Lenz F, Mechoulam R . Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res. 2004; 132(1):87-92. DOI: 10.1016/j.molbrainres.2004.08.025. View

20.

Steffens M, Szabo B, Klar M, Rominger A, Zentner J, Feuerstein T . Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience. 2003; 120(2):455-65. DOI: 10.1016/s0306-4522(03)00318-x. View